CAT3, a prodrug of 13a(S)-3-hydroxyl-6,7-dimethoxyphenanthro[9,10-b]-indolizidine, circumvents temozolomide-resistant glioblastoma via the Hedgehog signaling pathway, independently of O6-methylguanine DNA methyltransferase expression
OncoTargets and Therapy (2018)
Institution: Institute of Materia Medica, China
Cell Line: U251/TMZ and T98G (TMZ-resistant glioblastoma cell lines)
Research Area: Cancer research
Conclusions: The results indicate that CAT3 is a potential therapeutic agent for TMZ-resistant GBM (glioblastoma multiforme). HoloMonitor M4 was used to directly monitor and calculate the cell number.